DailyIQ
Last updatedUpdating…

ABT·Abbott Laboratories

$98.16
-1.94 (-1.94%)
Pre-Market
High
$98.49
Open
$98.49
Market Cap
173.11B
52W High
$135.13
Low
$98.49
P. Close
$98.16
P/E
31.91
52W Low
$81.97
Fwd P/E
16.18
DailyIQ Est.
$123.61
Inst. Ownership
26.2%
Short Interest
1.13%
Days to Cover
2.6
Technical Score (1D)
14
BEARISH
News Sentiment
43
BEARISH
On Oct 6, Abbott (ABT) closed down 1.94% at $98.16, trailing the S&P 500 and Nasdaq. The decline followed a 7.6% month‑to‑date loss for the company, reflecting a broader 4.26% fall in the medical sector. Investors noted that Abbott’s upcoming earnings on Oct 21 are expected to show a 10% EPS increase to $1.43 and a 13.5% revenue rise to $12.91 billion. Analysts highlighted that the consensus estimates for the full year remain positive, with earnings projected at $5.52 per share and revenue at $50.32 billion. The market reaction underscored the company’s recent performance relative to sector peers and the anticipation of the forthcoming earnings report.
LOW TARGET
$103 +4.9%
2 analysts
MEAN TARGET
$121 +22.8%
16 analysts
HIGH TARGET
$135 +37.5%
17 analysts
PRICE RANGE
$103.00 - $135.00
SB / B / H / S / SS
12/13/8/1/1
DAILYIQ EST.
$123.61 (+25.9%)
Sector
Healthcare
Industry
Medical Devices
Exchange
NYQ
Country
United States
Website
Symbol
ABT
Description
Abbott Laboratories is a global healthcare company focused on the discovery, development, and commercialization of a diverse portfolio of health products. The company operates across four main segments: established pharmaceuticals, diagnostics, nutritionals, and medical devices. Abbott's established pharmaceuticals division offers generic medications addressing a range of conditions, while its diagnostics segment provides laboratory systems and rapid testing solutions for infectious diseases and other health concerns. The company's nutritional products encompass pediatric and adult offerings, and its medical devices segment develops products for cardiovascular health, diabetes care, and neuromodulation. Founded in 1888, Abbott Laboratories is headquartered in North Chicago, Illinois.
Bought (1Y)
2,000 shares
$174K
Sold (1Y)
458,485 shares
$52.4M
Roman Michael F-
Award/Grant381 shares2026-09-30
Ahuja Nita-
Award/Grant318 shares2026-09-30
Conroy Kevin T-
Award/Grant318 shares2026-09-30
Gonzalez Patricia Paola-
Award/Grant333 shares2026-09-30
Stratton John G-
Award/Grant397 shares2026-09-30
78/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
56.4%
Net Margin
14.7%
Revenue CAGR
3.0%
Current Ratio
1.58x
Debt / Equity
0.25x
Return on Equity
12.5%
Earnings Summary
Abbott Laboratories, a long‑standing global healthcare company headquartered in North Chicago, Illinois, operates across four core segments—established pharmaceuticals, diagnostics, nutritionals, and medical devices—positioning it firmly within the medical devices sector. In the most recent quarters, Abbott’s earnings trajectory has been largely steady: Q4 2025 revenue fell to $11.46 billion versus the $11.94 billion reported in Q3 2025, while EPS slipped to $1.50 from $1.30 in Q3 2025, indicating a modest deceleration in profitability; however, the company still beat analyst expectations in Q4 2025, reporting $1.50 versus an estimate of $1.5115. The preceding quarter, Q1 2026, saw revenue rise to $11.16 billion and EPS climb to $1.15, narrowly surpassing the $1.14622 estimate, and Q2 2026 delivered $12.59 billion in revenue and $1.31 EPS against a $1.42199 forecast, again beating expectations. Historically, Abbott has maintained a positive YoY revenue growth trend, with Q2 2026 revenue up 5.5% from Q2 2025, while EPS growth has been more volatile, reflecting margin pressures in its diagnostics and medical device lines. The company has consistently outperformed estimates in the last four quarters, with EPS beats in three of those periods and revenue beats in two, underscoring a resilient earnings model despite sector headwinds. Recent regulatory news—most notably the FDA approval on October 5, 2026 of interactive features for the CardioMEMS Heart Monitor and the CardioGuide HF App—expands Abbott’s remote‑monitoring portfolio and may support future revenue streams; additionally, the launch of the SimpleScreen CRC blood‑based test in September 2026 broadens its diagnostics offerings.

EPS

EstBeatMiss
$1.09$1.21$1.33$1.45$1.57Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$1.41 - -
Q2'26$1.42$1.31-7.9%
Q1'26$1.15$1.15+0.3%
Q4'25$1.51$1.50-0.8%
Q3'25$1.30$1.30+0.0%
Q2'25$1.26$1.26+0.3%

Revenue

EstBeatMiss
$10.7B$11.4B$12.1B$12.7B$13.4BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$13.1B - -
Q2'26$12.6B$12.6B-0.2%
Q1'26$11.0B$11.2B+1.5%
Q4'25$11.9B$11.5B-3.9%
Q3'25 - $11.4B -
Q2'25 - $11.1B -

Market Data

ABT Stock Snapshot

BEARISH14/100
$98.49+$0.10 (0.1%)
Market cap
173.11B
P/E ratio
31.9
Day range
$98.49 – $98.49
News sentiment
43/100 · Neutral
Analyst target
$120.58 (+22.4%)
Consensus
Buy · 35 analysts
52-week range+20.2% off low · -27.1% from high
$81.97$135.13
Price $98.49 DailyIQ Est. $123.61

The chart on ABT has not stabilised: price is in the lower half of its 52-week range and the trend is still down. Sector peers are worth watching - large caps in Healthcare tend to move together on rotation.

Reverse DCF

What growth is priced into ABT?

RICH

At today's price, Abbott Laboratories needs to grow free cash flow about 4.9% a year for the next 10 years to justify its valuation at a 7.19% cost of capital. Over its actual history it has compounded free cash flow at 1.8% a year, so the market is asking for 3.1 percentage points above its own delivered rate. On that basis ABT looks priced above what its own growth record supports.

Implied FCF growth
4.9%
Historical FCF CAGR
1.8%
Growth gap
+3.1 pts
Verdict
RICH
Discount rate (WACC)
7.19%
Beta
0.45

Behaviour On Record

What ABT's own history says about today's numbers

Realized volatility (21d)
21.0% 57th pct
Below its peak
-29.4%
vs 200-day average
-3.7%
Up days (1y)
46%

Abbott Laboratories is currently running 21.0% annualised volatility over the last 21 sessions. Measured against ABT's own 13 years of daily returns rather than a market-wide average, that is the 57th percentile — close to its own typical level, against a typical reading of 19.7%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

ABT is trading -29.4% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -17.2%, and the deepest was -31.9% in 2022. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits -3.7% from its 200-day moving average. Against every other day in its history, that gap ranks at the 21st percentile — a narrower gap than it typically runs. Over the past year ABT closed higher on 46% of sessions, and it is currently 2 sessions into a rising streak.

On October specifically: over 13 years of records, ABT finished the month higher 7 of 13 times, with a median return of +1.3% and an average of +1.3%. Its strongest month historically has been July at +4.4% on average, its weakest September at -1.6%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: ABT has opened more than 2% away from the prior close in 42 of 3,266 sessions (1.3% of the time), with the largest gaps running +11.5% and -5.2%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, ABT moved an average of 1.9% in the session after earnings, closing higher 2 of those 3 times, with a median move of +1.6% and a largest of -2.0%.

All figures computed from 3,267 daily closes between 2013-10-07 and 2026-10-05, split-adjusted, recomputed daily. Percentiles are against ABT's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of ABT's sector?

Abbott Laboratories sits in the Health Care sector, currently ranked 3rd of 12 GICS sectors by relative-strength rotation score (lagging). Within its narrower Medical Devices industry group, ABT ranks 5th of 15 tracked industries, lagging.

Sector rank
#3 of 12
Sector state
Lagging
Sector rotation score
36
Industry rank
#5 of 15

Options Market

What is the options market pricing for ABT?

CallsPuts

For Abbott Laboratories's nearest expiry (2026-11-20, 44 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.00), with at-the-money implied volatility around 0.8%. The options market is pricing roughly a ±0.3% move by that expiry — a range of about $97.09–$97.61.

Put/call ratio (2026-11-20)
0.00
ATM implied volatility
0.8%
Total open interest
14
Expected move by 2026-11-20
±0.3% ($97.09–$97.61)

Analyst Rating Changes

Are analysts turning bullish or bearish on ABT?

Rothschild & Co most recently upgraded Abbott Laboratories to Buy on Oct 2, 2026 with a price target of $127 (from $119). Over the last 90 days, coverage has run 2 upgrades against 0 downgrades, a net bullish lean.

Latest action
Rothschild & Co — Buy
90-day upgrades
2
90-day downgrades
0
Net rating momentum
+2
DateFirmActionRatingPrice target
Oct 2, 2026Rothschild & CoUpgradeNeutral → Buy$119 → $127
Sep 8, 2026TD CowenReiteratedBuy$135
Aug 25, 2026TD CowenMaintainedBuy$115 → $135
Aug 21, 2026TD CowenMaintainedBuy$115 → $135
Aug 14, 2026CitigroupMaintainedBuy$112 → $125
Aug 13, 2026Wolfe ResearchUpgradePeer Perform → Outperform$130
Jul 28, 2026UBSMaintainedBuy$135 → $125
Jul 17, 2026CitigroupMaintainedBuy$108 → $112
Jul 17, 2026Piper SandlerReiteratedOverweight$115 → $118
Jul 17, 2026JP MorganMaintainedOverweight$110 → $120
Jul 17, 2026Wells FargoMaintainedOverweight$109 → $112
Jul 17, 2026TD CowenReiteratedBuy$115

ABT Competitive Positioning

Abbott Laboratories (ABT) is tracked alongside these names in Medical Devices on DailyIQ — ranked by market cap, with today's move alongside.

News Sentiment Analysis

Sentiment gathered from recent headlines

43/100
Strong NegativeNeutralStrong Positive
BEARISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
On October 6, Abbott (ABT) closed down 1.94% at $98.16, lagging the S&P 500 and Nasdaq. The decline followed a 7.6% month‑to‑date loss for the company, while the medical sector fell 4.26%. Investors noted that Abbott’s upcoming earnings on October 21 are expected to show a 10% EPS increase to $1.43 and a 13.5% revenue rise to $12.91 billion. Analysts highlighted that the consensus estimates for the full year remain positive, with earnings projected at $5.52 per share and revenue at $50.32 billion.
What did this article say?
MarketsandMarkets projected the global disposable medical device market to rise from USD 113.95 billion in 2025 to USD 144.85 billion by 2030, a CAGR of 4.9%. The growth is driven by heightened infection‑prevention focus, chronic disease prevalence, an aging population, increased surgical volumes, and expanding long‑term care demand. Key industry players include Johnson & Johnson, Baxter, BD, Cardinal Health, Abbott, and Medtronic. The forecast signals a moderate tailwind for companies in the sector, including ABT, but does not indicate a material shift in ABT’s outlook.
What did this article say?
Abbott Laboratories (ABT) secured U.S. Food and Drug Administration approval on October 5 for interactive capabilities in its CardioMEMS Heart Monitor. The new technology enables real‑time heart‑pressure updates to patients and allows clinicians to transmit medication adjustments via smartphones. Abbott plans to launch the CardioGuide HF App and Dynamic Treatment Plan later in the year, expanding its remote‑monitoring portfolio. This approval enhances ABT’s position in chronic heart failure management and could drive future adoption of its sensor‑based solutions.
What did this article say?
Abbott secured U.S. FDA approval for updates to its CardioMEMS HF System, adding patient-facing features via the CardioGuide HF App. The new capabilities allow patients to view pulmonary artery pressure readings on their smartphones and receive personalized medication updates. This enhancement is expected to improve early detection of heart failure deterioration and encourage proactive patient involvement between clinical visits.
What did this article say?
On October 5, 2026, Zacks.com listed Abbott Laboratories (ABT) among its featured low‑beta healthcare stocks for the Analyst Blog. The blog noted that the healthcare sector offers defensive positioning amid volatile markets and potential future interest rate hikes. Abbott was highlighted alongside Corcept Therapeutics, Precigen, and Bausch Health as a candidate for investors seeking stability. The piece emphasized the broader macro environment, including inflation concerns and geopolitical tensions, as context for the selection. No specific financial guidance or performance metrics for ABT were disclosed.
What did this article say?
Evercore ISI increased its price target for Abbott Laboratories (ABT) to $124 from $120 while keeping an outperform rating. The firm cited the company’s strong earnings outlook and robust product pipeline as reasons for the upward revision. The adjustment signals confidence in ABT’s growth prospects and may influence investor sentiment.
What did this article say?
Abbott Laboratories (ABT) received U.S. Food and Drug Administration approval on October 5 for an updated version of its CardioMEMS Heart Failure System. The revision adds patient-facing capabilities that allow users to monitor and manage their condition more effectively. The approval expands the system’s utility and could broaden its adoption among clinicians and patients. This regulatory milestone is expected to support ABT’s revenue growth in the medical device segment.
What did this article say?
Rothschild & Co upgraded Abbott Laboratories (ABT) from Neutral to Buy on October 2. The rating change reflects confidence in the company’s earnings outlook and product pipeline. The upgrade signals a positive view of ABT’s market position and potential for future growth. Investors may view the move as a catalyst for a modest rally in the stock price.
What did this article say?
Analysts highlighted Abbott Laboratories (ABT) as a low‑beta defensive option for investors wary of another Federal Reserve rate hike. The piece noted that ABT’s stable earnings and diversified product portfolio make it resilient in a high‑inflation environment. By positioning ABT alongside other healthcare names, the article suggested it could outperform during market volatility. The recommendation was framed as a strategic buy for risk‑averse portfolios.
What did this article say?
Rothschild & Co’s Redburn division upgraded Abbott Laboratories (ABT) from neutral to buy, citing stronger earnings outlook and product pipeline momentum. The firm lifted its price target to $127 from $119, reflecting expectations of higher margin expansion. The upgrade follows recent guidance revisions and a favorable macro environment for medical device sales.

Technical Analysis

Real-time indicators across multiple timeframes

14
BEARISH
Technical indicators reflect the latest computed signal mix for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $41.11B combined position · 10 adding, 11 trimming, 4 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
BlackRock, Inc.▲ Buy152,563,4768.68%$13.84B2026-08-07
Geode Capital Management, LLC▲ Buy39,219,3372.23%$3.54B2026-08-12
Capital Research Global Investors▼ Sell36,908,9902.10%$3.35B2026-08-12
Morgan Stanley▼ Sell26,611,3151.51%$2.41B2026-08-13
Norges Bank• Hold23,354,9111.33%$2.12B2026-08-12
Goldman Sachs Group Inc▲ Buy18,604,5701.06%$1.69B2026-08-14
Northern Trust Corp▼ Sell18,273,3011.04%$1.66B2026-08-13
Bank of America Corp▼ Sell17,672,5431.01%$1.60B2026-08-14
JPMorgan Chase & Co▼ Sell15,113,7980.86%$1.40B2026-08-12
Wells Fargo & Company▼ Sell15,185,3170.86%$1.38B2026-08-14
FMR LLC (Fidelity)▲ Buy13,423,0800.76%$1.22B2026-08-13
Citadel Advisors LLC• Hold12,066,9270.69%$1.09B2026-09-02
Janus Henderson Group plc• Hold8,092,9170.46%$830.86M2026-05-18
Invesco Ltd.▼ Sell8,817,2400.50%$800.08M2026-08-14
Wellington Management Group LLP▼ Sell8,304,7090.47%$753.57M2026-08-14
Two Sigma Investments, LP▲ Buy8,221,1150.47%$745.98M2026-08-14
Susquehanna International Group, LLP▲ Buy4,983,6200.28%$452.21M2026-08-14
Millennium Management LLC▲ Buy4,405,4940.25%$399.75M2026-08-14
AQR Capital Management LLC▲ Buy4,193,0580.24%$380.48M2026-08-14
Citigroup Inc▲ Buy3,779,8980.22%$342.99M2026-08-03
AllianceBernstein L.P.▼ Sell2,999,0500.17%$307.91M2026-08-14
Neuberger Berman Group LLC▼ Sell2,558,1110.15%$232.26M2026-08-13
Adage Capital Partners GP, L.L.C.▲ Buy2,332,1150.13%$211.62M2026-08-14
Maverick Capital Ltd• Hold1,758,1600.10%$180.51M2026-05-15
D. E. Shaw & Co., Inc.▼ Sell1,816,8920.10%$164.86M2026-08-14
Q2 2026 flow:44.96M sh bought ($4.08B)59.98M sh sold ($5.52B)net -15.01M sh (−$1.44B)
Congressional Trading Activity
25 disclosed trades · ~$265.5K est. traded value · 8 buys, 16 sells
MemberChamberStateTypeAmountTradedFiled
Richard Dean Dr McCormickHouseGA06▼ Sell$1K - $15K2026-07-302026-08-14
Mike KellyHousePA16▼ Sell$1K - $15K2026-07-172026-08-12
Richard W. AllenHouseGA12▼ Sell$15K - $50K2026-07-142026-08-18
Rick LarsenHouseWA02▼ Sell$1K - $15K2026-07-082026-07-12
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-06-162026-07-02
Richard Dean Dr McCormickHouseGA06▲ Buy$1K - $15K2026-06-122026-07-09
Josh GottheimerHouseNJ05▼ Sell$1K - $15K2026-05-272026-06-03
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2026-05-152026-06-08
Julie JohnsonHouseTX32▼ Sell$1K - $15K2026-05-122026-06-12
Richard W. AllenHouseGA12▼ Sell$15K - $50K2026-04-162026-06-05
Alan ArmstrongSenateOK▼ Sell$15K - $50K2026-03-272026-07-21
Laura FriedmanHouseCA30↔ Exchange$1K - $15K2026-03-242026-04-17
Richard Dean Dr McCormickHouseGA06▲ Buy$1K - $15K2026-03-192026-04-07
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2026-02-102026-03-09
Thomas H. KeanHouseNJ07▲ Buy$1K - $15K2026-01-292026-02-19
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2025-12-192026-01-12
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-12-182026-01-15
Julia LetlowHouseLA05▼ Sell$1K - $15K2025-12-082026-01-13
Byron DonaldsHouseFL19▼ Sell$1K - $15K2025-12-042026-01-07
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-11-182025-12-15
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-11-132025-12-11
Richard Dean Dr McCormickHouseGA06▲ Buy$1K - $15K2025-11-052025-12-09
Rick LarsenHouseWA02▲ Buy$1K - $15K2025-10-062025-10-16
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-08-142025-09-11
Thomas H. KeanHouseNJ07▲ Buy$1K - $15K2025-07-212025-08-20